Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Boehringer Ingelheim
Citi
Harvard Business School
Fish and Richardson
Federal Trade Commission
Farmers Insurance
Argus Health
Express Scripts

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,585,115

« Back to Dashboard

Summary for Patent: 5,585,115
Title: Pharmaceutical excipient having improved compressability
Abstract:A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.
Inventor(s): Sherwood; Bob E. (Amenia, NY), Hunter; Edward A. (Glenham, NY), Staniforth; John H. (Bath, GB2)
Assignee: Edward H. Mendell Co., Inc. (Patterson, NY)
Application Number:08/370,576
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 5,585,115

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,585,115

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 5830399 ➤ Sign Up
Brazil 9605245 ➤ Sign Up
Brazil 9605329 ➤ Sign Up
Canada 2183881 ➤ Sign Up
Canada 2183882 ➤ Sign Up
Germany 69627934 ➤ Sign Up
Germany 69638015 ➤ Sign Up
Germany 69638054 ➤ Sign Up
Denmark 0752848 ➤ Sign Up
European Patent Office 0749300 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Cipla
Daiichi Sankyo
Argus Health
Cerilliant
Accenture
McKinsey
Covington
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot